Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
Go back to Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors| Merck & Co. (NYSE: MRK) | Delayed: 148.66 -0.12 (0.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.78 | 52 Week High | $65.46 | |||
| Open | $147.65 | 52 Week Low | $47.97 | |||
| Day High | $149.19 | P/E | 101.13 | |||
| Day Low | $146.28 | EPS | $1.47 | |||
| Volume | 3,496,676 | |||||
